PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune sys...

Full description

Saved in:
Bibliographic Details
Published inCell reports (Cambridge) Vol. 25; no. 11; pp. 2972 - 2980.e5
Main Authors Ding, Liya, Kim, Hye-Jung, Wang, Qiwei, Kearns, Michael, Jiang, Tao, Ohlson, Carolynn E., Li, Ben B., Xie, Shaozhen, Liu, Joyce F., Stover, Elizabeth H., Howitt, Brooke E., Bronson, Roderick T., Lazo, Suzan, Roberts, Thomas M., Freeman, Gordon J., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Zhao, Jean J.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 11.12.2018
Elsevier
Subjects
Online AccessGet full text
ISSN2211-1247
2211-1247
DOI10.1016/j.celrep.2018.11.054

Cover

Loading…
More Information
Summary:PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune system remain unclear. We find that PARP inhibition by olaparib triggers robust local and systemic antitumor immunity involving both adaptive and innate immune responses through a STING-dependent antitumor immune response in mice bearing Brca1-deficient ovarian tumors. This effect is further augmented when olaparib is combined with PD-1 blockade. Our findings thus provide a molecular mechanism underlying antitumor activity by PARP inhibition and lay a foundation to improve therapeutic outcome for cancer patients. [Display omitted] •T cell-mediated cytotoxicity is important for therapeutic activity of PARP inhibition•Olaparib-treated Brca1-deficient tumor cells activate the STING pathway in APCs•STING pathway activation is required for the antitumor efficacy of PARP inhibition•PD-1 blockade enhances the antitumor efficacy of olaparib in Brca1-deficient tumors Ding et al. show that PARP inhibition in Brca1-deficient tumors elicits strong antitumor immunity involving activation of both innate and adaptive immune responses, a process that is dependent on STING pathway activation. In addition, they show that addition of PD-1 blockade augments the therapeutic efficacy of PARP inhibitor treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
L.D., H.-J.K., Q.W., P.A.K., U.A.M., and J.J.Z. designed the study. L.D., H.-J.K., and Q.W. performed the experiments. L.D., H.-J.K., Q.W., and J.J.Z. analyzed data. C.E.O., T.J., and M.K. helped with mouse model generation and in vivo treatment. S.L. helped with the flow cytometry analysis. B.E.H. and R.T.B. performed histological analysis. B.B.L. performed the GSEA analyses. J.F.L., E.H.S., B.B.L., P.A.K., T.M.R., and G.J.F. contributed to scientific discussions. L.D., H.-J.K., Q.W., B.B.L., G.J.F., P.A.K., U.A.M., and J.J.Z. wrote and reviewed the manuscript.
AUTHOR CONTRIBUTIONS
ISSN:2211-1247
2211-1247
DOI:10.1016/j.celrep.2018.11.054